Karuna Therapeutics, Inc.

Bristol Myers Squibb made a $14bn gamble when it agreed to buy Karuna Therapeutics in late 2023 for its drug that was pending US Food and Drug Administration approval at the time of the acquisition. T

China’s retaliatory tariffs mean the option of manufacturing US-originated drugs in China is making more sense than ever, at least to some local partners of US pharmaceutical companies. China imposed

It looks as though nothing will come of the takeover talks PureTech Health has held with Nordic Capital Epsilon but there is a compelling argument for taking its ‘hub-and-spoke’ business private in th

The second half of this decade will put the Bristol Myers Squibb management team to the test as the company prepares for losses of exclusivity (LOEs) for its three top-selling products by launching up